Skip to main content
← Back to Science Explained

Therapy history

Place modern peptide drugs inside a longer research story

Insulin, GLP-1 drugs, dual agonists, and newer candidates did not appear from nowhere. This series follows the drug landscape from discovery to engineered duration.

How to compare

01Origin story
02Regulatory status
03Molecular design

Read the drug landscape

  1. 01The line from insulin to Ozempic runs through a century of discoveryHistory of insulin explains the Ozempic era better than hype does: identify a useful signal, map its biology, then engineer delivery and stability so the same pathway becomes medically usable.
  2. 02Dozens of peptide drugs already carry FDA approvalSome peptide drugs are FDA approved. Approval is specific to a product, indication, data package, manufacturing quality, and regulatory review; it does not transfer to every peptide, research product, compounded product, or chemically similar molecule.
  3. 03Ozempic, Mounjaro, and Retatrutide each hit a different set of receptorsSemaglutide vs tirzepatide comparisons usually start with weight loss, but pathway design is the real difference. Each generation adds one more signal target, from single-pathway GLP-1 drugs to triple-agonist retatrutide.
  4. 04Semaglutide is 94% identical to GLP-1, and the other 6% changes everythingSemaglutide explained in one line: the molecule keeps most of native GLP-1's receptor-recognized shape, then adds targeted edits that extend duration from minutes to about a week.